67th ASH Annual Meeting & Exposition — December 6–9, 2025 — Orlando, Florida

Resumen

of novel and innovative models increasingly available for studying lymphoma, with a particular emphasis on the tumor microenvironment. Overall, the session aims to enhance understanding of how these models can be optimally utilized to advance knowledge of lymphoma biology and treatment effects, facilitating the translation of research findings into clinical applications. The presentations will cover ex vivo and in vivo models, including refined lymphoma transplantation strategies and genetically engineered mouse models, focusing on their individual strengths and limitations. Dr. Ankur Singh will present recent advancements in engineering synthetic ex vivo models of human lymphomas, including bioengineered lymphoid organoids informed by tumor microenvironment data, and explore how these models reveal mechanisms of therapy resistance and the role of tumor-immune interactions. Dr. Michael Green will discuss the development and application of patient-derived xenograft models for studying large B-cell lymphoma, highlighting their molecular heterogeneity and their use in identifying factors that influence responses to small molecules and cellular therapies. Dr. Wendy Beguelin will highlight the use of genetically engineered mouse models for studying genetically defined lymphoma subtypes within an immunocompetent setting, discussing their potential to recapitulate the natural progression of the disease and the challenges posed by their complex genetic alterations. Chair: Oliver Weigert, MD Ludwig-Maximilians-University (LMU) Hospital Munich, Germany